Vania Hungria
0000-0002-4327-1957
9 papers found
Refreshing results…
Perforin and granzyme B gene expression is associated with a short survival time in patients with multiple myeloma
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA
Health‐related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis
Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel – ABHH monoclonal gammopathies committe
Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries
Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice
Missing publications? Search for publications with a matching author name.